Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Research & Development (2016 - 2025)

Cumberland Pharmaceuticals' Research & Development history spans 16 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Research & Development rose 19.88% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $5.6 million, up 15.58%, while the annual FY2025 figure was $5.6 million, 15.58% up from the prior year.
  • Research & Development for Q4 2025 was $1.5 million at Cumberland Pharmaceuticals, up from $1.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $1.9 million in Q3 2023 and bottomed at $1.1 million in Q2 2024.
  • The 5-year median for Research & Development is $1.4 million (2022), against an average of $1.4 million.
  • The largest annual shift saw Research & Development soared 38.79% in 2022 before it tumbled 37.21% in 2023.
  • A 5-year view of Research & Development shows it stood at $1.6 million in 2021, then dropped by 12.83% to $1.4 million in 2022, then skyrocketed by 36.91% to $1.9 million in 2023, then plummeted by 32.84% to $1.3 million in 2024, then increased by 19.88% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for CPIX's Research & Development are $1.5 million (Q4 2025), $1.3 million (Q3 2025), and $1.5 million (Q2 2025).